Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Adicet Bio Inc (NQ: ACET )

1.015 -0.085 (-7.73%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 4, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Adicet Bio Inc

< Previous 1 2 3 4 Next >
Adicet Bio to Participate in 2024 Canaccord Genuity Horizons in Oncology Virtual Conference
From Adicet Bio, Inc.
Via Business Wire
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
From Adicet Bio, Inc.
Via Business Wire
Adicet Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress
From Adicet Bio, Inc.
Via Business Wire
Adicet Bio to Participate in a Fireside Chat at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
From Adicet Bio, Inc.
Via Business Wire
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
From Adicet Bio, Inc.
Via Business Wire
Adicet Bio to Participate in a Fireside Chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
From Adicet Bio, Inc.
Via Business Wire
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
From Adicet Bio, Inc.
Via Business Wire
Adicet Bio, Inc. Announces Closing of $98 Million Public Follow-On Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
From Adicet Bio, Inc.
Via Business Wire
Adicet Bio, Inc. Announces Pricing of Public Offering
From Adicet Bio, Inc.
Via Business Wire
Adicet Bio, Inc. Announces Proposed Public Offering
From Adicet Bio, Inc.
Via Business Wire
Adicet Provides Corporate Update and Highlights Strategic Priorities for 2024
From Adicet Bio, Inc.
Via Business Wire
Adicet Bio to Host Conference Call to Provide Updates on its Clinical Pipeline and Corporate Outlook
From Adicet Bio, Inc.
Via Business Wire
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
From Adicet Bio, Inc.
Via Business Wire
Adicet Bio Highlights ADI-001 Expansion, Persistence and Pharmacodynamic Profile from Ongoing Phase 1 Study at the 65th American Society of Hematology (ASH) Annual Meeting
From Adicet Bio, Inc.
Via Business Wire
Adicet Reports Third Quarter 2023 Financial Results and Provides Business Updates
From Adicet Bio, Inc.
Via Business Wire
Adicet Bio to Present at the 2023 Jefferies London Healthcare Conference
From Adicet Bio, Inc.
Via Business Wire
Adicet Bio Announces Poster Presentation Highlighting ADI-001 Data at the 65th American Society of Hematology (ASH) Annual Meeting
From Adicet Bio, Inc.
Via Business Wire
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
From Adicet Bio, Inc.
Via Business Wire
Adicet Bio Announces Poster Presentation at the Upcoming 2023 Molecular Targets and Cancer Therapeutics Conference
From Adicet Bio, Inc.
Via Business Wire
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Adicet Bio, Inc.
Via Business Wire
Adicet Bio to Present Three Scientific Posters Highlighting its Allogeneic Gamma Delta T Cell Platform and Programs at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
From Adicet Bio, Inc.
Via Business Wire
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Adicet Bio, Inc.
Via Business Wire
Adicet Reports Second Quarter 2023 Financial Results and Provides Business Updates
From Adicet Bio, Inc.
Via Business Wire
Adicet Bio to Participate in a Fireside Chat at the Canaccord Genuity 43rd Annual Growth Conference
From Adicet Bio, Inc.
Via Business Wire
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Adicet Bio, Inc.
Via Business Wire
Adicet Announces Appointment of Katie Peng to the Board of Directors
From Adicet Bio, Inc.
Via Business Wire
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Adicet Bio, Inc.
Via Business Wire
Adicet Bio Reports Positive Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL)
From Adicet Bio, Inc.
Via Business Wire
Adicet Bio to Participate in a Fireside Chat at the 2023 Jefferies Healthcare Conference
From Adicet Bio, Inc.
Via Business Wire
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Adicet Bio, Inc.
Via Business Wire
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.